Dr. Vu has been awarded a grant supporting her work to develop combination therapies to treat patients with T-cell acute lymphoblastic leukemia (T-ALL), a disease with a very poor prognosis. She is testing inhibitors targeting both the so-called mixed lineage leukemia 1 (MLL1) protein and the NOTCH1 protein, to weaken T-ALL cells and make them more susceptible to treatment.
Content courtesy of Leukemia & Lymphoma Society
Straube J, Lane SW, Vu T. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes. Bioessays. 2021.